| Safety, activity, and immune correlates of anti–PD-1 antibody in cancer SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ... New England Journal of Medicine 366 (26), 2443-2454, 2012 | 14223 | 2012 |
| PD-1 blockade in tumors with mismatch-repair deficiency DT Le, JN Uram, H Wang, BR Bartlett, H Kemberling, AD Eyring, ... New England Journal of Medicine 372 (26), 2509-2520, 2015 | 9968 | 2015 |
| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ... Science 357 (6349), 409-413, 2017 | 6406 | 2017 |
| Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates JR Brahmer, CG Drake, I Wollner, JD Powderly, J Picus, WH Sharfman, ... Journal of clinical oncology 28 (19), 3167-3175, 2010 | 3664 | 2010 |
| Pancreatic cancer D Li, K Xie, R Wolff, JL Abbruzzese The Lancet 363 (9414), 1049-1057, 2004 | 2760 | 2004 |
| Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy SL Topalian, JM Taube, RA Anders, DM Pardoll Nature Reviews Cancer 16 (5), 275-287, 2016 | 2680 | 2016 |
| Elucidation of a universal size-control mechanism in Drosophila and mammals J Dong, G Feldmann, J Huang, S Wu, N Zhang, SA Comerford, ... Cell 130 (6), 1120-1133, 2007 | 2607 | 2007 |
| Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti–PD-1 therapy JM Taube, A Klein, JR Brahmer, H Xu, X Pan, JH Kim, L Chen, DM Pardoll, ... Clinical cancer research 20 (19), 5064-5074, 2014 | 2600 | 2014 |
| Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape JM Taube, RA Anders, GD Young, H Xu, R Sharma, TL McMiller, S Chen, ... Science translational medicine 4 (127), 127ra37-127ra37, 2012 | 2463 | 2012 |
| Fulminant myocarditis with combination immune checkpoint blockade DB Johnson, JM Balko, ML Compton, S Chalkias, J Gorham, Y Xu, ... New England Journal of Medicine 375 (18), 1749-1755, 2016 | 2145 | 2016 |
| The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints NJ Llosa, M Cruise, A Tam, EC Wicks, EM Hechenbleikner, JM Taube, ... Cancer discovery 5 (1), 43-51, 2015 | 1542 | 2015 |
| Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAP Y Liu-Chittenden, B Huang, JS Shim, Q Chen, SJ Lee, RA Anders, JO Liu, ... Genes & development 26 (12), 1300-1305, 2012 | 1454 | 2012 |
| Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria CM Dejea, P Fathi, JM Craig, A Boleij, R Taddese, AL Geis, X Wu, ... Science 359 (6375), 592-597, 2018 | 943 | 2018 |
| The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals N Zhang, H Bai, KK David, J Dong, Y Zheng, J Cai, M Giovannini, P Liu, ... Developmental cell 19 (1), 27-38, 2010 | 862 | 2010 |
| A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung cancer DL Rimm, G Han, JM Taube, SY Eunhee, JA Bridge, DB Flieder, R Homer, ... JAMA oncology 3 (8), 1051-1058, 2017 | 770 | 2017 |
| Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas Y Jiao, TM Pawlik, RA Anders, FM Selaru, MM Streppel, DJ Lucas, ... Nature genetics 45 (12), 1470-1473, 2013 | 715 | 2013 |
| Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology AB Benson, MI D’Angelica, DE Abbott, DA Anaya, R Anders, C Are, ... Journal of the National Comprehensive Cancer Network 19 (5), 541-565, 2021 | 708 | 2021 |
| Expression of Yes-associated protein in common solid tumors AA Steinhardt, MF Gayyed, AP Klein, J Dong, A Maitra, D Pan, ... Human pathology 39 (11), 1582-1589, 2008 | 681 | 2008 |
| Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody EJ Lipson, WH Sharfman, CG Drake, I Wollner, JM Taube, RA Anders, ... Clinical Cancer Research 19 (2), 462-468, 2013 | 671 | 2013 |
| LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems JF Grosso, CC Kelleher, TJ Harris, CH Maris, EL Hipkiss, A De Marzo, ... The Journal of clinical investigation 117 (11), 3383-3392, 2007 | 660 | 2007 |
Andrew PardollJohns Hopkins University school of medicineEmail verificata su jhmi.edu